Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture
C García‐Crespo, AI de Ávila, I Gallego… - British journal of …, 2024 - Wiley Online Library
Background and Purpose There is a need for effective anti‐COVID‐19 treatments, mainly for
individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug …
individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug …
Exploring nucleoside analogs: key targets in the viral life cycle-advancing strategies against SARS-CoV-2
R Garg, R Kumar, R Srivastava… - Medicinal Chemistry …, 2024 - Springer
The COVID-19 pandemic has been a major reason behind the increased research aimed at
the identification of effective antiviral agents. Among these, Nucleoside analogs have shown …
the identification of effective antiviral agents. Among these, Nucleoside analogs have shown …
Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono-and Co-infection with Human Immunodeficient Virus or SARS-CoV-2
D Yan, B Yan - Current Drug Metabolism, 2023 - ingentaconnect.com
Monkeypox is a zoonotic viral disease and remains endemic in tropical regions of Central
and West Africa. Since May of 2022, cases of monkeypox have soared and spread …
and West Africa. Since May of 2022, cases of monkeypox have soared and spread …
Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model
RT Kiy, SH Khoo, AE Chadwick - Toxicology research, 2024 - academic.oup.com
Abstract Background β-d-N4-Hydroxycytidine (NHC) is the active metabolite of molnupiravir,
a broad-spectrum antiviral approved by the MHRA for COVID-19 treatment. NHC induces …
a broad-spectrum antiviral approved by the MHRA for COVID-19 treatment. NHC induces …
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B. 1 and BQ. 1.1 SARS-CoV-2 Viral Variants
L Fiaschi, C Biba, I Varasi, N Bartolini, C Paletti… - Viruses, 2024 - mdpi.com
Combination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection;
however, no clinical trial data are available, and combined use of direct-acting antivirals …
however, no clinical trial data are available, and combined use of direct-acting antivirals …
Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 …
ES Istifli, N Okumus, C Sarikurkcu… - Journal of …, 2023 - Taylor & Francis
Abstract Molnupiravir (EIDD-2801)(MLN) is an oral antiviral drug for COVID-19 treatment,
being integrated into viral RNA through RNA-dependent RNA polymerase (RdRp). Upon …
being integrated into viral RNA through RNA-dependent RNA polymerase (RdRp). Upon …
Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19
L Zeng, R Chen, X Jiang, F Li, Z Zhu… - Fundamental & …, 2024 - Wiley Online Library
Background The pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of
nirmatrelvir (NMV) are unknown in Chinese patients with COVID‐19. Objectives To …
nirmatrelvir (NMV) are unknown in Chinese patients with COVID‐19. Objectives To …